UnknownPhase 2

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

United States75 participantsStarted 2020-01-31

Plain-language summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group comparison study of AT-5214 in subjects with moderate to severe primary palmar hyperhidrosis (sweaty palms). This study will compare two different oral (tablet) doses of AT-5214 (study drug) versus a matched placebo. Approximately 120 subjects will be enrolled at approximately 10 study sites.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Iontophoresis to the palms within four weeks prior to baseline visit;
✕. Botulinum toxin to the palms within one year prior to baseline visit;
✕. Prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands);
✕. Prior medical device treatment to the palms (approved or investigational);
✕. Any prescription treatments for hyperhidrosis within four weeks prior to baseline visit.
✕. Any topical antiperspirant treatment to the palms within 7 days prior to baseline visit.

What they're measuring

PHIS Reduction

Timeframe: Week 6 (End of Study)

Trial details

NCT IDNCT04263623

SponsorAtacama Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-12-03

View on ClinicalTrials.gov More Hyperhidrosis trials